Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report
| Autor: | Daniela Di Mauro, Giovanni Gobbin, Francesca Martini, Marco Meazza Prina, Cristina Giussani, Anna Fargnoli, Andrea D'Alessio, Marco Motta, Monica Taverna, Federico Bracchi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Ruxolitinib
medicine.medical_specialty Pediatrics Case Report Disease Infectious and parasitic diseases RC109-216 Asymptomatic Lymphohistiocytosis Hemophagocytic Medical microbiology Pandemic medicine Humans Pandemics Etoposide business.industry SARS-CoV-2 fungi COVID-19 Middle Aged medicine.disease Polyserositis Cytokine release syndrome Infectious Diseases Female medicine.symptom Cytokine storm business Cytokine Release Syndrome Hemophagocytic syndrome medicine.drug |
| Zdroj: | BMC Infectious Diseases BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-5 (2021) |
| ISSN: | 1471-2334 |
| Popis: | Background Hemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient’s recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection. Case presentation We describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib. Conclusions Our report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink